Related references
Note: Only part of the references are listed.Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Philip A. Philip et al.
CLINICAL CANCER RESEARCH (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy
Joanne Lundy et al.
FRONTIERS IN ONCOLOGY (2021)
White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease
Naveen M. Kulkarni et al.
ABDOMINAL RADIOLOGY (2020)
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Louis Buscail et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Neoadjuvant Treatment in Pancreatic Cancer
Atsushi Oba et al.
FRONTIERS IN ONCOLOGY (2020)
Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies.
Andrew Eugene Hendifar et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma
Caitlin A. McIntyre et al.
CANCER (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical Effect of Driver Mutations of KRAS, CDKN2A/P16, TP53, and SMAD4 in Pancreatic Cancer: A Meta-Analysis
Yujun Gu et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2020)
Impact of resection margin status on recurrence and survival in pancreatic cancer surgery
W. S. Tummers et al.
BRITISH JOURNAL OF SURGERY (2019)
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers
Aatur D. Singhi et al.
GASTROENTEROLOGY (2019)
Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma
Etienne Buscail et al.
CANCERS (2019)
Pancreatic cancer An update on diagnosis and management
Benjamin P. T. Loveday et al.
AUSTRALIAN JOURNAL OF GENERAL PRACTICE (2019)
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
Shuji Isaji et al.
PANCREATOLOGY (2018)
Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma
Zhi Rong Qian et al.
JAMA ONCOLOGY (2018)
Pancreatic Adenocarcinoma, Version 2.2017
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Sushrut Kamerkar et al.
NATURE (2017)
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
Jonas Cicenas et al.
CANCERS (2017)
KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
Barbara Bournet et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Genetics and Biology of Pancreatic Ductal Adenocarcinoma
Richard F. Dunne et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2015)
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
Talia Golan et al.
ONCOTARGET (2015)
The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies
Lorenzo Fuccio et al.
GASTROINTESTINAL ENDOSCOPY (2013)
Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer
Takeshi Ogura et al.
JOURNAL OF GASTROENTEROLOGY (2013)
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
Stefan Boeck et al.
JOURNAL OF GASTROENTEROLOGY (2013)
Genetic Alterations of K-ras, p53, c-erbB-2, and DPC4 in Pancreatic Ductal Adenocarcinoma and Their Correlation With Patient Survival
Sang Hyun Shin et al.
PANCREAS (2013)
Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival
P. Sivaramakrishna Rachakonda et al.
PLOS ONE (2013)
Pancreatic Adenocarcinoma, Version 2.2012 Featured Updates to the NCCN Guidelines
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Share Paper
